Escalation Threshold for Intermediate-High-Risk Pulmonary Embolism: Anticoagulation Alone or Catheter-Directed Therapy
Priya's pulmonary embolism has left her right ventricle strained and her troponin elevated, but her blood pressure has never wavered. Whether that stability is reassuring or just not yet informative is what the team actually disagrees about.
Priya D., a 58-year-old woman, flew home twelve days ago from a monthlong overseas posting managing a client project on-site — a grueling stretch of sixteen-hour days and long-haul flights she'd been proud to pull off — and had been back at her desk job for less than a week when the chest tightness and sudden breathlessness sent her to the emergency department rather than back to her laptop. CT pulmonary angiography showed bilateral pulmonary emboli, with filling defects extending into both main pulmonary arteries. Her blood pressure on arrival was 118/76 and has stayed there — she is, by the numbers that matter most for immediate triage, hemodynamically stable. But her echocardiogram tells a less reassuring story: a right ventricle visibly larger than her left, an RV/LV ratio of 1.3, with reduced tricuspid annular plane systolic excursion, and her troponin returned at 0.09 ng/mL, roughly twice the upper limit of normal for the assay in use. That combination — normal blood pressure with both imaging evidence of RV strain and biochemical evidence of myocardial stress — is the definition of intermediate-high risk — and it is worth being precise about what that does not establish. The two markers move her out of the intermediate-low group and no further. Her RV/LV ratio of 1.3 sits at the shallow end of what counts as dilation at all, nearer the 1.0 that merely qualifies than the frankly dilated ventricles the reperfusion literature's success stories are built on.
Anticoagulation alone is the guideline-preferred initial strategy here, and the trial that set that preference describes Priya almost exactly. PEITHO (Meyer and colleagues, 2014) enrolled 1,006 normotensive patients who had, as a condition of entry, both RV dysfunction on imaging and a positive troponin — dual positivity was not a subgroup within PEITHO, it was PEITHO. Full-dose tenecteplase cut death or hemodynamic decompensation at seven days from 5.6% to 2.6%, and charged for it: major extracranial bleeding rose from 1.2% to 6.3%, stroke from 0.2% to 2.4%, and mortality did not move. The number the team keeps returning to sits in the placebo arm — better than nine in ten of these patients, all dual-positive, did not decompensate on anticoagulation alone. What changed since was not a finding that dual positivity marks a higher tier, but PEITHO's own investigators asking what else, on top of those two markers, predicts deterioration, and building the next reperfusion trials around the answer. Priya's chart is about to be read against that answer rather than against her echocardiogram, and the reading may not go the way the echocardiogram suggests.
Emergency department, PE risk-stratification discussion
She's hemodynamically normal and has been for the entire time we've had her. PEITHO is the best evidence we have at this risk tier, and I want to be careful about how we're using it: every one of those 1,006 patients had RV dysfunction and a positive troponin, because that was the entry criterion. Dual positivity isn't a subgroup that PEITHO's average result fails to describe — it is the population PEITHO studied. And what it found was that lysing them cut decompensation from 5.6% to 2.6% while pushing major extracranial bleeding from 1.2% to 6.3% and stroke from 0.2% to 2.4%, with no mortality benefit at all. More than nine in ten of the patients randomized to heparin alone — all dual-positive, like her — never decompensated. I don't want to reach for reperfusion before she's shown us she's in the other tenth.
I'll concede the framing — you're right that I can't call her dual positivity a reason she sits outside PEITHO, because it's the reason she sits inside it. But PEITHO tested full-dose systemic tenecteplase, and I'm not proposing that. Catheter-directed therapy exists precisely because that bleeding column was the thing worth engineering around, not a reason to abandon reperfusion.
The relevant trial is HI-PEITHO, which put ultrasound-facilitated catheter-directed thrombolysis against anticoagulation alone rather than against placebo, and the safety picture is a different animal: major bleeding 4.1% versus 3.0%, not significant, and no intracranial hemorrhage in either arm. What moved was rescue therapy — 2.9% with the catheter against 9.2% without it. That is the number I'd hang this on. "Nine in ten do fine" is a statement about a population; the nine in ten weren't the ones who needed the catheter at two in the morning, and I would rather place it in daylight than at the moment somebody's pressure is falling.
Then let's finish reading HI-PEITHO's entry criteria, because they're the part that decides this. It didn't enrol on RV dysfunction and troponin alone — it required at least two additional clinical distress criteria on top: a systolic pressure at or below 110 for fifteen minutes, a heart rate of 100 or more, a respiratory rate above 20 or resting hypoxemia. Those criteria came out of PEITHO's own post-hoc work looking for who actually deteriorates, and they are the field's current answer. The one we can read off Priya's chart with certainty is the blood pressure, and she has never been at or below 110 — she came in at 118 systolic and has not moved. So before anyone commits, I want the other two charted properly: serial heart rate and respiratory rate, documented, not remembered. Start anticoagulation now and set a genuinely low escalation threshold — continuous telemetry, serial lactate and troponin, interventional radiology aware — so that if she begins meeting those criteria, the catheter goes in within the hour. Her stability isn't the absence of evidence. It's the evidence, and right now it says she is below the bar both of the trials you've each cited used to decide who gets reperfused.
Agreed: anticoagulation started now, with continuous telemetry, serial biomarker monitoring, documented serial heart rate and respiratory rate, and catheter-directed escalation triggered by onset of any two HI-PEITHO clinical distress criteria.
Not agreed: the interventional cardiologist would still have placed the catheter tonight, on the view that a trial's entry criteria describe who was studied rather than who benefits, and that the rescue-therapy gap is a reason to act before the criteria are met rather than after. The pulmonologist would set the trigger at frank hemodynamic compromise alone, and regards borrowing HI-PEITHO's distress criteria as a threshold for a procedure that trial's own patients qualified for on top of them as a category error running in the opposite direction. The hospitalist's trigger was adopted without either of them conceding it was the right one.